PROSPECT LIFE SCIENCES – FDA 483, Nov 17, 2022
An FDA inspection of PROSPECT LIFE SCIENCES, a medical device contract manufacturer in Westminster, CO, revealed two significant observations. The firm was cited for inadequate documentation of corrective and preventive action (CAPA) activities, specifically regarding root cause investigations and verification of effectiveness. Additionally, the inspection found deficiencies in the company's procedures for receiving, reviewing, and evaluating product complaints, including a lack of requirements to review relevant quality data sources during investigations.
ID · 05a28a30-3d16-4d5b-9f3f-844193a3c6fe
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.